Acer Therapeutics Inc represents a commitment to developing innovative therapeutics to address unmet medical needs. The company's corporate philosophy centers around providing effective treatment options for patients who may have limited or no approved therapies available. Acer aims to prioritize patient health and well-being through rigorous research, clinical development, and regulatory processes. By leveraging its expertise and resources, Acer strives to make a positive impact on the lives of individuals with rare diseases and other serious medical conditions. Through its dedication to scientific innovation and patient-centric approach, Acer Therapeutics Inc aims to improve global healthcare outcomes.

Acer Therapeutics Inc is primarily present in the United States.

Acer Therapeutics Inc, a leading biopharmaceutical company, has achieved several significant milestones. The company successfully received U.S. Food and Drug Administration (FDA) Fast Track designation for its flagship product, Edsivo™, for the treatment of vEDS, a life-threatening genetic disorder. Additionally, Acer Therapeutics Inc completed a successful Phase 2 clinical trial for Edsivo™, demonstrating its potential in treating vEDS patients. The company also obtained Orphan Drug designation from the FDA for ACER-001, a fully taste-masked and immediate-release formulation of sodium phenylbutyrate, intended to treat patients with urea cycle disorders. Acer Therapeutics Inc's milestones highlight their commitment to innovation and addressing unmet medical needs in rare diseases.

Acer Therapeutics Inc. is a pharmaceutical company with a rich history and background. Founded in 2017, Acer is dedicated to developing and commercializing innovative therapies for rare and life-threatening diseases. The company focuses on creating treatments for serious conditions, including vascular Ehlers-Danlos syndrome (vEDS) and maple syrup urine disease (MSUD), among others. With a strong commitment to patient care, Acer Therapeutics strives to make a positive impact on the lives of individuals suffering from these rare diseases. Its research and development efforts underscore the company's mission to improve treatment options and enhance the quality of life for affected patients.

The main competitors of Acer Therapeutics Inc in the market include companies such as BioMarin Pharmaceutical Inc, Strongbridge Biopharma plc, and Ultragenyx Pharmaceutical Inc.

Acer Therapeutics Inc is primarily active in the biotechnology industry.

The business model of Acer Therapeutics Inc revolves around the development and commercialization of innovative therapies for rare and life-threatening diseases. As a pharmaceutical company, Acer focuses on identifying and advancing potential treatments to address unmet medical needs. By conducting rigorous research and clinical trials, Acer aims to bring novel therapies to patients who may have limited treatment options. This includes leveraging partnerships, collaborations, and strategic acquisitions to expand their pipeline and accelerate the development process. Ultimately, Acer Therapeutics Inc strives to improve the quality of life for individuals affected by rare diseases through the delivery of effective and accessible treatment solutions.

Raportul Acer Therapeutics preț/beneficiu este 3,48.

Raportul Acer Therapeutics preț/vânzări este 0,21.

Scorul de calitate AlleAktien pentru Acer Therapeutics este 5/10.

Cifra de afaceri a așteptată Acer Therapeutics este de 49,40 milioane USD.

Profitul așteptată Acer Therapeutics este 2,99 milioane USD.

Acer Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for rare diseases. It is headquartered in Cambridge, Massachusetts and was founded in 2017. The business model of Acer Therapeutics is based on the identification, development, and marketing of drugs for the treatment of rare diseases. The company focuses on diseases that currently have no effective treatment options and utilizes innovative technologies based on advanced scientific knowledge. Acer Therapeutics' portfolio includes various product candidates in different stages of development. One of the key products is the drug Edsivo, developed for the treatment of Vascular Ehlers-Danlos Syndrome (vEDS). vEDS is a rare connective tissue disorder that can lead to life-threatening vascular complications and has had no specific therapies available until now. Edsivo is currently in Phase III of clinical development and has been granted "Breakthrough Therapy" status by the US Food and Drug Administration (FDA), which allows for accelerated approval. Another product of Acer Therapeutics is ACER-001, developed for the treatment of Urea Cycle Disorders, a group of genetic disorders that result in a deficiency of enzymes necessary for ammonia metabolism in the body. ACER-001 is currently in Phase II of clinical development and has been granted "Orphan Drug" status by the FDA, which provides special advantages in market approval. Additional product candidates of Acer Therapeutics are ACER-801, being developed for the treatment of Phenylketonuria, and ACER-2820, which could be suitable for the treatment of Niemann-Pick Disease Type C. Both products are still in preclinical development. The business model of Acer Therapeutics is to successfully develop and bring these products to market, utilizing a combination of internal development activities and strategic partnerships with other companies and research institutions. Acer Therapeutics has already entered into several collaborations with renowned partners to accelerate and optimize the development of its product candidates. Acer Therapeutics finances its activities through a combination of equity financing and debt financing. Since its inception, the company has conducted multiple successful financing rounds, raising several million US dollars in total. In summary, Acer Therapeutics' business model is focused on developing and bringing innovative therapies for rare diseases to market. The company relies on innovative technologies, strategic partnerships, and sustainable financing. With its portfolio of promising product candidates, Acer Therapeutics has the potential to significantly impact the rare disease market and improve the lives of millions of people.

Acer Therapeutics distribuie un dividend de 0 USD în plăți anuale.

Dividenda nu poate fi calculată în prezent pentru Acer Therapeutics sau compania nu distribuie dividende.

Codul ISIN pentru Acer Therapeutics este US00444P1084.

Codul WKN al Acer Therapeutics este A2DYQV.

Ticker-ul pentru Acer Therapeutics este ACER.

În ultimele 12 luni, Acer Therapeutics a plătit un dividend în valoare de . Aceasta corespunde unei randamente a dividendului de aproximativ . Pentru următoarele 12 luni, Acer Therapeutics va plăti probabil un dividend de 0 USD.

Randamentul dividendelor pentru Acer Therapeutics este în prezent de .

Acer Therapeutics plătește un dividend trimestrial. Acesta este distribuit în lunile .

Acer Therapeutics a plătit dividende în fiecare an, în ultimii 0 ani.

Pentru următoarele 12 luni se așteaptă dividende în valoare de 0 USD. Acest lucru corespunde unei randamente a dividendelor de 0 %.

Acer Therapeutics este atribuit sectorului 'Sănătate'.

Pentru a primi ultimul dividend de Acer Therapeutics de la 26.09.2024 în valoare de 0 USD, trebuia să deții acțiunea în portofoliu înainte de ziua Ex-Tag de pe 26.09.2024.

Ultima plată a dividendului a fost efectuată la 26.09.2024.

În anul 2023, Acer Therapeutics a distribuit 0 USD sub formă de dividende.

Dividendele de la Acer Therapeutics sunt distribuite în USD.